Northern Trust Corp Has $3.32 Million Position in ChemoCentryx Inc (NASDAQ:CCXI)

Northern Trust Corp boosted its holdings in ChemoCentryx Inc (NASDAQ:CCXI) by 15.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 357,403 shares of the biopharmaceutical company’s stock after buying an additional 47,396 shares during the period. Northern Trust Corp’s holdings in ChemoCentryx were worth $3,323,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Marshall Wace North America L.P. acquired a new position in ChemoCentryx in the first quarter valued at approximately $235,000. 361 Capital LLC lifted its holdings in ChemoCentryx by 326.3% in the second quarter. 361 Capital LLC now owns 197,562 shares of the biopharmaceutical company’s stock valued at $1,837,000 after buying an additional 151,219 shares during the period. Acadian Asset Management LLC increased its stake in ChemoCentryx by 6.2% in the second quarter. Acadian Asset Management LLC now owns 823,080 shares of the biopharmaceutical company’s stock valued at $7,656,000 after purchasing an additional 47,957 shares in the last quarter. BB&T Securities LLC increased its stake in ChemoCentryx by 3.0% in the second quarter. BB&T Securities LLC now owns 138,827 shares of the biopharmaceutical company’s stock valued at $1,291,000 after purchasing an additional 4,000 shares in the last quarter. Finally, Fosun International Ltd increased its stake in ChemoCentryx by 40.2% in the second quarter. Fosun International Ltd now owns 128,637 shares of the biopharmaceutical company’s stock valued at $1,150,000 after purchasing an additional 36,861 shares in the last quarter. Institutional investors and hedge funds own 64.27% of the company’s stock.

Shares of NASDAQ:CCXI opened at $7.59 on Friday. ChemoCentryx Inc has a 52 week low of $6.16 and a 52 week high of $14.98. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.57 and a current ratio of 3.57. The company has a market capitalization of $440.60 million, a PE ratio of -9.99 and a beta of 1.15. The company has a 50 day moving average price of $7.06 and a two-hundred day moving average price of $9.51.

ChemoCentryx (NASDAQ:CCXI) last issued its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.05). ChemoCentryx had a negative net margin of 144.27% and a negative return on equity of 103.61%. The firm had revenue of $7.17 million during the quarter, compared to the consensus estimate of $10.08 million. On average, sell-side analysts forecast that ChemoCentryx Inc will post -1.04 earnings per share for the current year.

Several brokerages have commented on CCXI. Zacks Investment Research downgraded shares of ChemoCentryx from a “hold” rating to a “sell” rating in a research note on Tuesday. ValuEngine raised shares of ChemoCentryx from a “buy” rating to a “strong-buy” rating in a research note on Thursday. JPMorgan Chase & Co. raised shares of ChemoCentryx from a “neutral” rating to an “overweight” rating and lowered their target price for the company from $16.00 to $14.00 in a research note on Thursday, September 12th. Finally, BidaskClub raised shares of ChemoCentryx from a “sell” rating to a “hold” rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. ChemoCentryx has an average rating of “Buy” and an average price target of $17.57.

ChemoCentryx Profile

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.

Further Reading: What is the strike price in options trading?

Want to see what other hedge funds are holding CCXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChemoCentryx Inc (NASDAQ:CCXI).

Institutional Ownership by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.